Allspring Global Investments Holdings LLC reduced its holdings in Hologic, Inc. (NASDAQ:HOLX – free report ) by 1.5% during the first quarter, according to its latest 13F filing with the SEC. The company now holds 209,208 shares of the medical equipment provider’s stock after selling 3,293 shares during the period. Allspring Global Investments Holdings LLC held 0.09% of Hologic worth $16,310,000 as of its latest SEC filing.
Other hedge funds and institutional investors also modified their holdings of the stock. Congress Wealth Management LLC DE increased its holdings in shares of Hologic by 31.9% in the first quarter. Congress Wealth Management LLC DE now owns 139,726 shares of the medical equipment provider’s stock valued at $10,893,000 after purchasing an additional 33,809 shares during the period. Park Place Capital Corp increased its holdings in Hologic by 37.0% in the first quarter. Park Place Capital Corp now owns 1,078 shares of the medical equipment provider’s stock valued at $84,000 after purchasing an additional 291 shares during the period. Diversified Trust Co made a new investment in Hologic shares in the first quarter valued at approximately $1,286,000. Hennion & Walsh Asset Management Inc. increased its holdings in Hologic shares by 3.0% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 17,674 shares of the medical equipment provider’s stock valued at $1,378,000 after purchasing an additional 509 shares during the period. Finally, Toth Financial Advisory Inc. increased its holdings in Hologic shares by 81.1% during the first quarter. Toth Financial Advisory Inc. now owns 775 shares of the medical equipment provider’s stock valued at $60,000 after purchasing an additional 347 shares during the period. Institutional investors own 94.73% of the company’s stock.
Hologic Price Performance
HOLX shares opened trading at $74.10 on Friday. The company’s 50-day simple moving average is $74.06 and its 200-day simple moving average is $74.40. The company has a market capitalization of $17.29 billion, a price-to-earnings ratio of 37.81, a price-to-earnings ratio (P/E/G) of 2.45 and a beta of 0.99. Hologic, Inc.’s one-year low and high are $64.02 and $82.45, respectively. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29.
Hologic (NASDAQ:HOLX – Get free report ) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported quarterly earnings per share (EPS) of $1.03, beating analysts’ consensus estimates of $0.98 by $0.05. The company’s quarterly revenue was $1.02 billion, compared to analysts’ expectations of $1.0 billion. Hologic had net margins of 11.78% and return on equity of 18.91%. The company’s quarterly revenue was down 0.8% year-over-year. The company’s EPS was $1.06 during the same period last year. Research analysts expect Hologic, Inc. to post $4.08 EPS for the current fiscal year.
Analyst Rating Changes
A number of analysts have issued reports on the stock. Argus increased their price target on Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, May 9th. Needham & Company LLC raised their price target on Hologic to $90.00 and reverted their rating to a “buy” in a report on Friday, May 3rd. JPMorgan Chase & Co. raised their price target on Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. StockNews.com raised their price target on Hologic from a “hold” to a “buy” rating in a report on Friday, May 3rd. Finally, Stephens began researching shares of Hologic in a report on Thursday, June 27th. The firm gave the company an “overweight” rating and a $87.00 price target. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating, giving the company a moderate buy consensus rating and an average price target of $85.55, according to MarketBeat.com data.
Check out the latest stock report on Hologic
Hologic Company Profile
(Free report)
Hologic, Inc develops, manufactures and supplies diagnostic products, medical imaging systems and surgical products that support women’s health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, Gynecologic Surgical and Skeletal Health. It offers Aptima molecular diagnostic assays to detect infectious microorganisms; Aptima viral load assays for Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus and Human Cytomegalovirus; Aptima Bacterial Vaginosis and Candida Vaginitis Assays for diagnosing vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 Assays to detect SARS-CoV-2; ThinPrep Systems for cytology applications; and a rapid fetal fibronectin test to help physicians assess the risk of preterm birth.
Feature Articles
Receive Hologic Daily news and reviews –Enter your email address below to receive a concise summary of the latest news and analyst ratings on Hologic and related companies every day via MarketBeat.com’s free email newsletter.
